CMAC’s vision is to revolutionise the way pharmaceuticals and high-value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, postdocs, and more than 45 PhD students, as well as an experienced support team.
